Browsing by Author "Ozdemir, M."

Now showing 1 - 6 of 6

The Clinical Features, Risk Factors and Treatment Methods of Patients With Acute Coronary Syndrome
(Excerpta Medica inc-elsevier Science inc, 2014) Aladag, N.; Yurtdas, M.; Ozdemir, M.; Gonullu, H.; Babat, N.; Demir, G.; Gumrukcuoglu, H.
Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey
(Sage Publications inc, 2016) Aslan, Onur; Yaylali, Y. T.; Yildirim, S.; Yurtdas, M.; Senol, H.; Ugur-Yildiz, M.; Ozdemir, M.
Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 patients prescribed dabigatran (n = 220) or warfarin (n = 219). Ischemic stroke occurred in 15 (6.8%) patients in the warfarin group versus 5 (5.2%) patients in the 110-mg group versus 1 (0.8%) patient in the 150-mg dabigatran group (P = .015). Intracranial hemorrhage occurred in 6 (2.7%) patients in the warfarin group versus 3 (2.4%) patients in the 150-mg dabigatran group (P = .104). Death from any cause occurred in 10 (4.6%) patients in the warfarin group versus 1 (1.0%) patient in the 110-mg dabigatran group (P = .005). Dabigatran was associated with less ischemic stroke and death from any cause than warfarin. Dabigatran may be a better option for stroke prophylaxis, where recommended monitoring with warfarin is suboptimal.
Difficulties in Diagnosing Fabry Disease in Patients With Unexplained Left Ventricular Hypertrophy (Lvh): Is the Novel Gla Gene Mutation a Pathogenic Mutation or Polymorphism
(Sciendo, 2023) Aladag, N.; Barman, H. Ali; Sipal, A.; Akbulut, T.; Ozdemir, M.; Ceylaner, S.
Fabry disease (FD) is an X-linked, lysosomal glycosphingolipid storage disorder that occurs very rarely. Cardiac involvement may comprise of left ventricular hypertrophy (LVH), arrhythmias, conduction abnormalities, heart failure and valvular abnormalities. The goal of this study was to conduct gene analysis for FD in patients suffering from unexplained LVH. 120 patients over the age of 30 who were diagnosed by echocardiography with idiopathic LVH were included in the study. Patients with severe hypertension, intermediate valve disease such as moderate aortic stenosis, known FD, and a family history of autosomal dominant hypertrophic cardiomyopathy were excluded from the study. GLA gene mutations were studied by Sanger sequence analysis in all patients. Of the 120 total patients included in this study, 69 were female (58%) and 51 were male (42%). The mean age was 60.3 & PLUSMN; 15.7. GLA gene mutations were detected in three male patients. The detected mutations are as follows: NM_000169.2:IVS6-10G>A (c.1000-10G>A), NM_000169.2:c.937G>T (p.D313Y) (p.Asp313Tyr) and NM_000169.2:c.941A>T (p.K314M) (p.Lys314Met). Early diagnosis is of vital importance in FD, which can be treated with enzyme replacement. Genetic screening in patients diagnosed with idiopathic LVH by echocardiography is important in the early diagnosis and treatment of FD. Patients over 30 years of age with idiopathic LVH should be screened for FD. Various new polymorphisms can be detected in genetic screening. Identifying new polymorphisms is important for knowing the true mutations in FD.
Evaluation of Index of Cardiac Electrophysiological Balance in Covid-19 Patients
(Aepress Sro, 2021) Asoglu, R.; Tibilli, H.; Asoglu, E.; Aladag, N.; Ozdemir, M.; Suner, A.
AIM: The aim of the current study was to evaluate the index of Cardiac Electrophysiological Balance (iCEB) in hospitalized COVID-19 patients receiving Hydroxychloroquine / azithromycin (HCQ / AZ) combination therapy to determine the susceptibility to ventricular arrhythmia among these patients. METHOD: Sixty-seven COVID-19 patients admitted to the ward were included in the study. Electrocardiograms (ECGs) were obtained from all patients before the initiation of treatment and on treatment day 5. QT/QRS (iCEB) and QTc/QRS (iCEBc) ratios were calculated. RESULTS: QRS, QT and QTc intervals were signifi cantly prolonged on day 5 measurements compared to pre-treatment period (p <0.05). Overall, mean iCEB was 3.6 +/- 0.4 before treatment and 3.8 +/- 0.4 on day 5 in the study population (p <0.001). Considering the iCEBc values, a signifi cant increase was observed in patients receiving HCQ/AZ treatment compared to pre-treatment period (4.1 +/- 0.5 vs 4.4 +/- 0.6; p <0.001). CONCLUSIONS: To the best of our knowledge, this was the fi rst study to investigate iCEB and iCEBc parameters in patients with COVID-19 on HCQ/AZ therapy. In this study, we demonstrated signifi cantly increased iCEB and iCEBc values following HCQ/AZ treatment in COVID-19 patients. iCEB and iCEBc may serve as a noninvasive, simple, and novel biomarker for detecting increased pro-arrhythmia risk in COVID-19 patients (Tab. 3, Fig. 3, Ref. 36). Text in PDF www.elis.sk
Movable Thrombus Attached on Mitral Anterior Leaflet
(Elsevier Ireland Ltd, 2011) Gumrukcuoglu, H. A.; Odabasi, D.; Ekim, H.; Akdag, S.; Ozdemir, M.
Transradial Primary Percutaneous Coronary Intervention Is Associated With Low Rates of Clinical and Cardiovascular Events in Patients With Acute St Elevation Myocardial Infarction
(Excerpta Medica inc-elsevier Science inc, 2014) Yurtdas, M.; Kaya, Y.; Ozdemir, M.; Aladag, N.; Tosu, A. R.; Tuncer, M.